Evidence map›Paper›PMID 24828976›Full record

ArticleAnalytical and bioanalytical chemistry2014

Cannabinoids in oral fluid by on-site immunoassay and by GC-MS using two different oral fluid collection devices.

Nathalie A Desrosiers, Garry Milman, Damodara R Mendu, Dayong Lee, Allan J Barnes, David A Gorelick, Marilyn A Huestis

Open access · greenAbstract readEvaluation Study
In one paragraph

Article in Analytical and bioanalytical chemistry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
3.7field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 39 citations in OpenAlex.

  1. Trial
  2. Detection of ΔDrug testing and analysis · 2019
    Trial
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Aggressive Driving Behaviours in Cannabis Users. The Influence of Consumer Characteristics.International journal of environmental research and public health · 2021
    Article
  10. Effects of Smoking Cannabis on Visual Function and Driving Performance. A Driving-Simulator Based Study.International journal of environmental research and public health · 2020
    Article
  11. Review
  12. Article
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Nathalie A DesrosiersChemistry and Drug Metabolism Section, NIDA IRP, 251 Bayview Boulevard, Baltimore, MD, 21224, USA.
Garry Milman
Damodara R Mendu
Dayong Lee
Allan J Barnes
David A Gorelick
Marilyn A Huestis
National Institute on Drug Abuse · USMemorial Sloan Kettering Cancer Center · USUniversity of Florida · US

Funding

Pharmacokinetics And Pharmacodynamics Of Smoked Drugs Of AbuseZIADA000413 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI SCHEIDWEILER, KARL · 2009 to 2016
$6.0M
Detection Of Drugs Of Abuse In Alternative Biological Fluids And TissuesZIADA000412 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI SCHEIDWEILER, KARL · 2009 to 2016
$3.9M
Intramural NIH HHS ZIA DA000413
6 · The paper itself

Abstract

Oral fluid (OF) enables non-invasive sample collection for on-site drug testing, but performance of on-site tests with occasional and frequent smokers' OF to identify cannabinoid intake requires further evaluation. Furthermore, as far as we are aware, no studies have evaluated differences between cannabinoid disposition among OF collection devices with authentic OF samples after controlled cannabis administration. Fourteen frequent (≥4 times per week) and 10 occasional (less than twice a week) adult cannabis smokers smoked one 6.8% ∆(9)-tetrahydrocannabinol (THC) cigarette ad libitum over 10 min. OF was collected with the StatSure Saliva Sampler, Oral-Eze, and Draeger DrugTest 5000 test cassette before and up to 30 h after cannabis smoking. Test cassettes were analyzed within 15 min and gas chromatography-mass spectrometry cannabinoid results were obtained within 24 h. Cannabinoid concentrations with the StatSure and Oral-Eze devices were compared and times of last cannabinoid detection (t(last)) and DrugTest 5000 test performance were assessed for different cannabinoid cutoffs. 11-nor-9-Carboxy-THC (THCCOOH) and cannabinol concentrations were significantly higher in Oral-Eze samples than in Stat-Sure samples. DrugTest 5000 t(last) for a positive cannabinoid test were median (range) 12 h (4-24 h) and 21 h (1- ≥ 30 h) for occasional and frequent smokers, respectively. Detection windows in screening and confirmatory tests were usually shorter for occasional than for frequent smokers, especially when including THCCOOH ≥20 ng L(-1) in confirmation criteria. No differences in t(last) were observed between collection devices, except for THC ≥2 μg L(-1). We thus report significantly different THCCOOH and cannabinol, but not THC, concentrations between OF collection devices, which may affect OF data interpretation. The DrugTest 5000 on-site device had high diagnostic sensitivity, specificity, and efficiency for cannabinoids.

Indexed as

AdultAnalytic Sample Preparation MethodsCannabinoidsFemaleGas Chromatography-Mass SpectrometryHumansIllicit DrugsImmunoassayMaleMiddle AgedSalivaYoung AdultCannabinoidsIllicit Drugs

Identifiers

PMID24828976
PMCPMC4259565
OpenAlexW1997403976

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.